Last reviewed · How we verify

Salmeterol/Fluticasone Capsair® — Competitive Intelligence Brief

Salmeterol/Fluticasone Capsair® (Salmeterol/Fluticasone Capsair®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS). Area: Respiratory/Pulmonology.

marketed Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol/Fluticasone Capsair® (Salmeterol/Fluticasone Capsair®) — Neutec Ar-Ge San ve Tic A.Ş. Salmeterol/Fluticasone is a combination inhaled bronchodilator and corticosteroid that relaxes airway smooth muscle and reduces airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salmeterol/Fluticasone Capsair® TARGET Salmeterol/Fluticasone Capsair® Neutec Ar-Ge San ve Tic A.Ş marketed Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone Extra fine Formoterol/Beclomethasone National Institute of Respiratory Diseases, Mexico marketed Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate Salmeterol/ fluticasone propionate GlaxoSmithKline marketed Long-acting beta-2 agonist / inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/fluticasone Diskus Salmeterol/fluticasone Diskus AstraZeneca marketed Long-acting beta-2 agonist/inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide 500 Accuhaler Seretide 500 Accuhaler University of Southampton marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
FF/VI 100/25 Inhalation Powder NDPI FF/VI 100/25 Inhalation Powder NDPI GlaxoSmithKline phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor; glucocorticoid receptor
beta-II-agonist, inhale steroid beta-II-agonist, inhale steroid AstraZeneca phase 3 Beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) class)

  1. Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol/Fluticasone Capsair® — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-fluticasone-capsair. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: